<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">OR</journal-id>
<journal-title-group>
<journal-title>Oncology Reports</journal-title>
</journal-title-group>
<issn pub-type="ppub">1021-335X</issn>
<issn pub-type="epub">1791-2431</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/or.2017.5354</article-id>
<article-id pub-id-type="publisher-id">or-37-02-0913</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>MicroRNA-138-5p controls sensitivity of nasopharyngeal carcinoma to radiation by targeting EIF4EBP1</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Gao</surname><given-names>Wei</given-names></name>
<xref rid="af1-or-37-02-0913" ref-type="aff">1</xref>
<xref rid="fn1-or-37-02-0913" ref-type="author-notes">&#x002A;</xref></contrib>
<contrib contrib-type="author"><name><surname>Lam</surname><given-names>Jacky Wei Kei</given-names></name>
<xref rid="af1-or-37-02-0913" ref-type="aff">1</xref>
<xref rid="fn1-or-37-02-0913" ref-type="author-notes">&#x002A;</xref></contrib>
<contrib contrib-type="author"><name><surname>Li</surname><given-names>John Zeng-Hong</given-names></name>
<xref rid="af1-or-37-02-0913" ref-type="aff">1</xref>
<xref rid="af2-or-37-02-0913" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author"><name><surname>Chen</surname><given-names>Si-Qi</given-names></name>
<xref rid="af1-or-37-02-0913" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Tsang</surname><given-names>Raymond King-Yin</given-names></name>
<xref rid="af1-or-37-02-0913" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Chan</surname><given-names>Jimmy Yu-Wai</given-names></name>
<xref rid="af1-or-37-02-0913" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Wong</surname><given-names>Thian-Sze</given-names></name>
<xref rid="af1-or-37-02-0913" ref-type="aff">1</xref>
<xref rid="c1-or-37-02-0913" ref-type="corresp"/></contrib>
</contrib-group>
<aff id="af1-or-37-02-0913"><label>1</label>Department of Surgery, The University of Hong Kong, Hong Kong, SAR, P.R. China</aff>
<aff id="af2-or-37-02-0913"><label>2</label>Department of Otolaryngology, The First People&#x0027;s Hospital of Foshan, Foshan, Guangdong 528000, P.R. China</aff>
<author-notes>
<corresp id="c1-or-37-02-0913"><italic>Correspondence to</italic>: Dr Thian-Sze Wong, Department of Surgery, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong SAR, P.R. China, E-mail: <email>thiansze@gmail.com</email></corresp>
<fn id="fn1-or-37-02-0913"><label>&#x002A;</label><p>Contributed equally</p></fn>
</author-notes>
<pub-date pub-type="ppub"><month>01</month><year>2017</year></pub-date>
<pub-date pub-type="epub"><day>04</day><month>01</month><year>2017</year></pub-date>
<volume>37</volume>
<issue>2</issue>
<fpage>913</fpage>
<lpage>920</lpage>
<history>
<date date-type="received"><day>07</day><month>06</month><year>2016</year></date>
<date date-type="accepted"><day>26</day><month>10</month><year>2016</year></date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2017, Spandidos Publications</copyright-statement>
<copyright-year>2017</copyright-year>
</permissions>
<abstract>
<p>Radiation therapy is the standard treatment for primary nasopharyngeal carcinoma (NPC). MicroRNA regulates cancer responsiveness to radiation therapy by controlling the genes involved in radiation responses. Recent studies suggested that downregulation of microRNA-138-5p was clinically significant in NPC. Here, we evaluated the effect of miR-138-5p on radiosensitivity of NPC cells and explored the underlying mechanisms by identifying its target gene that impacted sensitivity to radiation. Our results revealed that overexpression of miR-138-5p reduced the ability to form colonies, inhibited proliferation, and enhanced radiation-induced DNA damage and autophagy in NPC cells upon radiation treatment. By integrating predicted targets with the transcripts downregulated by miR-138-5p, EIF4EBP1 was identified to be a target gene of miR-138-5p. Results from luciferase reporter assay demonstrated that miR-138-5p downregulated the expression of EIF4EBP1 by binding to the 3&#x2032;-UTR. Silence of EIF4EBP1 enhanced radiosensitivity of NPC cells as evidenced by reduced ability to form colonies after radiation exposure. In summary, our results indicated that miR-138-5p enhanced radiosensitivity of NPC cells by targeting EIF4EBP1. Further studies are warranted to investigate the potential use of miR-138-5p in the clinical management and treatment prediction of NPC patients.</p>
</abstract>
<kwd-group>
<kwd>nasopharyngeal carcinoma</kwd>
<kwd>microRNA-138-5p</kwd>
<kwd>radiation sensitivity</kwd>
<kwd>EIF4EBP1</kwd>
<kwd>DNA double-strand breaks</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Nasopharyngeal carcinoma (NPC) is a common head and neck cancer in southern China and Southeast Asia (<xref rid="b1-or-37-02-0913" ref-type="bibr">1</xref>). At present, radiotherapy is the major treatment for patients with undifferentiated NPC. Thus, the responsiveness of NPC cells to radiotherapy will have a direct impact on the treatment outcomes (<xref rid="b2-or-37-02-0913" ref-type="bibr">2</xref>). The reasons underlying the presentation of radiation resistant phenotype in a subgroup of patients remain poorly understood. In case of radiation treatment failure, patients will have high chance to develop distant metastasis and recurrent disease (<xref rid="b3-or-37-02-0913" ref-type="bibr">3</xref>&#x2013;<xref rid="b5-or-37-02-0913" ref-type="bibr">5</xref>). Although the use of molecular markers in predicting treatment outcome shows promising results in multiple solid tumors, the use of it in monitoring radiation response or prognostication remains limited in NPC (<xref rid="b6-or-37-02-0913" ref-type="bibr">6</xref>). Thus, there is a need to identify key molecular markers with predictive value in the NPC patients.</p>
<p>MicroRNA is a group of non-coding RNA which functions as post-transcriptional regulator in controlling specific gene expression (<xref rid="b7-or-37-02-0913" ref-type="bibr">7</xref>). Mature microRNA could form a thermodynamically stable duplex with the target mRNA by binding to the 3&#x2032; untranslated region (UTR) or open reading frame (<xref rid="b8-or-37-02-0913" ref-type="bibr">8</xref>). Binding to microRNA was able to hinder the translation process and suppress the corresponding protein level. In addition, the microRNA/mRNA duplex recruited Argonaute 2 (Ago2) forming the RNA-induced silencing complex (RISC) which subsequently promotes mRNA cleavage and degradation (<xref rid="b8-or-37-02-0913" ref-type="bibr">8</xref>). MicroRNA dysregulation has been reported in nearly all the human malignancies. Cancers had differential microRNA expression profiles depending on the cellular context. The differentially expressed or suppressed microRNA could contribute to the pathological development of specific cancer phenotype by regulating characteristic gene expression.</p>
<p>MicroRNA-138-5p expression was significant reduced in NPC tissues and NPC cell lines (<xref rid="b9-or-37-02-0913" ref-type="bibr">9</xref>). However, little is know about the functions of miR-138-5p in NPC. Liu <italic>et al</italic> performed a functional study on the role of miR-138-5p in NPC cell lines. They showed that re-introduction of miR-138-5p into the NPC cells could suppress the tumorigenicity of NPC cells <italic>in vivo</italic> (<xref rid="b9-or-37-02-0913" ref-type="bibr">9</xref>). In this study, we addressed the functional role of miR-138-5p in the responsiveness of NPC cells to radiation treatment. Computational analysis showed that miR-138-5p could potentially target the transcript of eukaryotic initiation factor 4E binding protein 1 (EIF4EBP1). EIF4EBP1 is a translational regulator (<xref rid="b10-or-37-02-0913" ref-type="bibr">10</xref>). EIF4EBP1 represses eukaryotic translation initiation factor 4E (eIF4E), the rate limiting cap-binding protein which regulates cap-dependent mRNA translation by binding to the 7-methyl-GTP 5&#x2032; capped end of the mRNA (<xref rid="b11-or-37-02-0913" ref-type="bibr">11</xref>). A recent study showed that increased EIF4EBP1 stability could promote therapeutic resistance in prostate cancer cell (<xref rid="b12-or-37-02-0913" ref-type="bibr">12</xref>). Therefore, we suggest that miR-138-5p could modulate the responsiveness to radiation treatment by targeting EIF4EBP1 in NPC.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Cell culture</title>
<p>Human NPC cell lines namely HONE1 and HK1, were derived from poorly and well differentiated NPC, respectively (<xref rid="b13-or-37-02-0913" ref-type="bibr">13</xref>,<xref rid="b14-or-37-02-0913" ref-type="bibr">14</xref>). HONE1 and HK1 cells were maintained in RPMI-1640 medium additionally supplemented with 10&#x0025; fetal bovine serum, 200 U/ml penicillin G sodium, 200 &#x00B5;g/ml streptomycin sulfate, and 0.5 &#x00B5;g/ml amphotericin B in a 37&#x00B0;C humidified incubator with 5&#x0025; CO<sub>2</sub>. Cell irradiation was performed by Gammacell<sup>&#x00AE;</sup> 3000 Elan system (Best Theratronics, Ottawa, ON, Canada).</p>
</sec>
<sec>
<title>miR-138 precursor transfection</title>
<p>HONE1 and HK1 cells were transiently transfected with miR-138 precursor and negative control (Applied Biosystems, Carlsbad, CA, USA) by HiPerFect reagent (Qiagen, Valencia, CA, USA) according to the manufacturer&#x0027;s protocol. After 72 h of transfection, cells were collected and the efficiency of miR-138 precursor transfection was determined.</p>
</sec>
<sec>
<title>Real-time quantitative RT-PCR (QPCR)</title>
<p>Total RNA was extracted by TRIzol (Life Technologies, Grand Island, NY, USA) according to the protocol of the manufacturer. High-Capacity cDNA Reverse Transcription kit (Applied Biosystems) was used for reverse transcription. Transcript levels of miR-138-5p and U6 control snRNA were measured by TaqMan Gene Expression assays (Applied Biosystems). The PCR primer-probe pairs for EIF4EBP1 were as follows: forward, 5&#x2032;-AGCCCTTCCAGTGATGAGC-3&#x2032;; reverse, 5&#x2032;-TGTCCATCTCAAACTGTGACTCTT-3&#x2032;; probe no. 21 of Universal ProbeLibrary (Roche Applied Science, Indianapolis, IN, USA). Primers were synthesized by Integrated DNA Technologies (Coralville, IA, USA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an endogenous control and quantified by Universal ProbeLibrary Human GAPD Gene assay (Roche Applied Science). The fold changes were calculated using 2<sup>&#x2212;&#x2206;&#x2206;Ct</sup> method.</p>
</sec>
<sec>
<title>Colony formation assay</title>
<p>Colony formation assay was carried out in 6-well cell culture plate with 600 cells per well. Cells were irradiated at a single dose of 2, 4, or 6 Gy and allowed to grow for two weeks. Then, colonies were stained with 0.5&#x0025; crystal violet after fixation with 70&#x0025; ethanol and colonies with &#x003E;50 cells were counted.</p>
</sec>
<sec>
<title>Proliferation assay</title>
<p>Proliferation assay was performed by using RTCA DP instrument of xCELLigence Real-Time Cell Analyzer (Roche Applied Science). Cells were inoculated into E-Plate 16 and were irradiated by Gammacell 3000 Elan system (Best Theratronics). The proliferation rates of HONE1 and HK1 cells were examined constantly.</p>
</sec>
<sec>
<title>&#x03B3;H2AX phosphorylation detection</title>
<p>HONE1 and HK1 cells were plated on chamber slides and irradiated at a single dose of 2, 4, or 6 Gy. Then, cells were washed, fixed and incubated with rabbit polyclonal anti-&#x03B3;H2AX antibodies (Abcam, Cambridge, UK) and CF&#x2122;488A Secondary Antibody Conjugates (Biotium, Hayward, CA, USA). Nucleus and F-actin were counterstained with DAPI (Life Technologies) and Alexa Fluor<sup>&#x00AE;</sup> 635 phalloidin (Life Technologies) respectively. Images were taken under a fluorescence microscope (Nikon, Tokyo, Japan) and the number of &#x03B3;H2AX foci in the cells was counted.</p>
</sec>
<sec>
<title>Acridine orange (AO) staining</title>
<p>AO (Sigma-Aldrich, St. Louis, MO, USA) staining was performed to detect the formation of acidic vesicular organelles (AVOs) during autophagy process. Cells were stained with AO at the concentration of 4 &#x00B5;g/ml for 15 min at 37&#x00B0;C. Stained cells were observed by a fluorescent microscope (Nikon).</p>
</sec>
<sec>
<title>Microarray</title>
<p>Affymetrix HG-U133 Plus 2 array (Affymetrix, Santa Clara, CA, USA) was used to detect global gene expression profiling. The quality of total RNA was evaluated using Agilent 2100 Bioanalyzer (Agilent Technologies). Data analysis was performed using GeneSpring version 13 (Agilent Technologies). Microarray was conducted by the Centre for Genomic Sciences, the University of Hong Kong.</p>
</sec>
<sec>
<title>Luciferase reporter assay</title>
<p>The sense and antisense strands of wild-type and mutant 3&#x2032;-UTR of EIF4EBP1 were synthesized. The oligonucleotides were as follows: wild-type sense strand: 5&#x2032;-CCAGGGCACCTGCCCCCTCCTCTTCGTGAACACCAGCAGATACCTCCTTGTGA-3&#x2032;; wild-type antisense strand: 5&#x2032;-AGCTTCACAAGGAGGTATCTGCTGGTGTTCACGAAGAGGAGGGGGCAGGTGCCCTGGAGCT-3&#x2032;; mutant sense strand: 5&#x2032;-CCAGGGCACCTGCCCCCTCCTCTTCGTGAAAGTACTAAGATACCTCCTTGTGA-3&#x2032;; mutant antisense strand: 5&#x2032;-AGCTTCACAAGGAGGTATCTTAGTACTTTCACGAAGAGGAGGGGGCAGGTGCCCTGGAGCT-3&#x2032;. The annealed sense and antisense strands of wild-type or mutant 3&#x2032;-UTR of EIF4EBP1 were cloned into the <italic>Sac</italic>I and <italic>Hin</italic>dIII sites of pMIR-Report Luciferase vector (Applied Biosystems) to produce Luc-wild-type or Luc-mutant construct, respectively. HONE1 cells were co-transfected with 200 ng Luc-wild-type vector or Luc-mutant vector, 50 nM miR-138 precursor or negative control (Applied Biosystems), together with 200 ng pMIR-Report &#x03B2;-galactosidase control vector (Applied Biosystems) using Lipofectamine 2000 (Life Technologies). After 48 h, firefly luciferase and &#x03B2;-galactosidase activities were determined using Dual-Light luminescent reporter gene assay kit (Applied Biosystems) on an LB 96V microplate luminometer (EG&#x0026;G Berthold, Bad Wildbad, Germany).</p>
</sec>
<sec>
<title>siRNA transfection</title>
<p>EIF4EBP1 siRNA-1, EIF4EBP1 siRNA-2 and negative control siRNA (Qiagen) were transfected into HONE1 and HK1 cells using HiPerFect transfection reagent (Qiagen) in accordance with the protocol from the manufacturer. After 72 h, cells were collected and the efficiency of EIF4EBP1 silencing was determined by QPCR.</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>Student&#x0027;s t-test was employed to compare quantitative variables between two groups. All the tests were 2-sided. Results were only considered statistically significant if p&#x003C;0.05.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>Overexpression of miR-138-5p enhanced the sensitivity of NPC cells to radiation</title>
<p>To evaluate the effect of miR-138-5p on radiosensitivity of NPC cells, we overexpressed miR-138-5p by transfection of miR-138 precursor. A dose-dependent increase in miR-138-5p expression was observed (<xref rid="f1-or-37-02-0913" ref-type="fig">Fig. 1A</xref>). Colony formation assay was performed to assess the sensitivity to radiation treatment. Cells transfected with 10 nM miR-138 precursor or negative control were exposed to radiation at the dose of 2, 4 or 6 Gy and the survival fraction was counted after 14 days. An apparent decrease in colony number was observed in cells transfected with miR-138 precursor in comparison with negative control under radiation treatment (<xref rid="f1-or-37-02-0913" ref-type="fig">Fig. 1B and C</xref>).</p>
</sec>
<sec>
<title>Overexpression of miR-138-5p inhibited proliferation and enhanced the &#x03B3;H2AX foci formation and autophagy of NPC cells under radiation treatment</title>
<p>The proliferation rate after radiation treatment was used to assess the radiosensitivity. Cells transfected with 10 nM miR-138 precursor were exposed to radiation at 24 hours after transfection and cell proliferation was continuously monitored. Although miR-138 precursor itself did not affect the proliferation rate of cells without radiation exposure, cells transfected with miR-138 precursor exhibited a significant reduction in proliferation rate in a time-dependent manner under radiation treatment (<xref rid="f2-or-37-02-0913" ref-type="fig">Fig. 2A and B</xref>). Radiation killed cells by inducing DNA double-strand breaks (DSBs). DSBs were recognized by varied protein complexes including &#x03B3;H2AX. Staining of cells with anti-&#x03B3;H2AX antibody generated foci corresponding to DSBs in nuclei (<xref rid="b15-or-37-02-0913" ref-type="bibr">15</xref>). Overexpression of miR-138-5p resulted in an obvious increase in the number of &#x03B3;H2AX foci after radiation treatment (<xref rid="f2-or-37-02-0913" ref-type="fig">Fig. 2C and D</xref>), indicating a higher degree of radiation-induced DNA damage. Radiation could induce autophagy in cancer cells. Formation of AVOs was a characteristic feature of autophagy. In AO-stained cells, cytoplasm and nucleolus displayed green fluorescence. In contrast, AVOs fluoresced bright red (<xref rid="b16-or-37-02-0913" ref-type="bibr">16</xref>). An increase in red signal was observed in NPC cells transfected with miR-138 precursor compared to negative control after exposure to radiation (<xref rid="f2-or-37-02-0913" ref-type="fig">Fig. 2E</xref>), implicating a higher level of radiation-induced autophagy.</p>
</sec>
<sec>
<title>miR138-5p directly targets EIF4EBP1</title>
<p>First, we used prediction databases to predict the targets of miR-138-5p. Considering that individual prediction database probably generated false positive targets, we employed Bioinformatics resource manager v2.3 (BRM) software (<uri xlink:href="http://www.sysbio.org/dataresources/brm.stm">http://www.sysbio.org/dataresources/brm.stm</uri>) for prediction (<xref rid="b17-or-37-02-0913" ref-type="bibr">17</xref>). BRM utilizes three databases including microCosm/miRBase, TargetScan and <uri xlink:href="http://miRNA.org">miRNA.org</uri> to predict targets. Those targets that are conserved across all three databases were considered as high-confidence ones. By the prediction function of BRM, 225 genes were predicted to be targets of miR-138-5p by all three databases. Given that miRNA promoted the degradation of target mRNA, we carried out microarray analysis to identify transcripts downregulated by miR-138-5p, which were its putative targets. The global gene expression profiling of HONE1 cells transfected with miR-138 precursor was examined. With a fold-change cut-off of 3 and p&#x003C;0.05, 186 genes were found to be downregulated by miR-138-5p. Then, the 225 high-confidence targets were integrated with the 186 transcripts downregulated by miR-138-5p. By this novel strategy, we identified 5 potential targets including DMKN, EIF4EBP1, NINJ1, PER1 and ST6GALNAC4 (<xref rid="f3-or-37-02-0913" ref-type="fig">Fig. 3A</xref>).</p>
<p>The binding sites between miR-138-5p and 3&#x2032;-UTR of EIF4EBP1 are shown in <xref rid="f3-or-37-02-0913" ref-type="fig">Fig. 3B</xref>. Results from QPCR further confirmed the downregulation of EIF4EBP1 by miR-138-5p (<xref rid="f3-or-37-02-0913" ref-type="fig">Fig. 3C</xref>). To explore whether miR-138-5p modulated the expression of EIF4EBP1 by binding to the 3&#x2032;-UTR, luciferase reporter assay was performed in HONE1 cells transfected with luciferase vector containing 3&#x2032;-UTR of EIF4EBP1 together with miR-138 precursor or negative control. Overexpression of miR-138-5p significantly reduced the luciferase activity of luciferase vector harboring wild-type 3&#x2032;-UTR of EIF4EBP1 (<xref rid="f3-or-37-02-0913" ref-type="fig">Fig. 3D</xref>). In contrast, mutation of the binding sites within 3&#x2032;-UTR of EIF4EBP1 abrogated the suppressing effect (<xref rid="f3-or-37-02-0913" ref-type="fig">Fig. 3D</xref>).</p>
<p>To gain insights into the clinical implications of EIF4EBP1 in NPC, the expression of EIF4EBP1 was analyzed in publicly available microarray dataset GSE12452 in the Oncomine database (<uri xlink:href="http://www.oncomine.org">www.oncomine.org</uri>) (<xref rid="b18-or-37-02-0913" ref-type="bibr">18</xref>). GSE12452 contained expression data of 31 NPC tissues and 10 normal controls. A 1.516-fold increase in EIF4EBP1 expression was observed in NPC tissues in comparison with normal controls (<xref rid="f3-or-37-02-0913" ref-type="fig">Fig. 3E</xref>).</p>
</sec>
<sec>
<title>Silence of EIF4EBP1 increased the sensitivity of NPC cells to radiation</title>
<p>To investigate the role of EIF4EBP1 in radiosensitivity of NPC cells, the expression of EIF4EBP1 was silenced by 2 specific siRNA. Transfection of siRNA at the concentration of 2.5 nM successfully inhibited the expression of EIF4EBP1 in HONE1 cells, while siRNA at the concentration of 10 nM was required to suppress the expression in HK1 cells (<xref rid="f4-or-37-02-0913" ref-type="fig">Fig. 4A</xref>). NPC cells transfected with EIF4EBP1 siRNA were exposed to radiation treatment at the dose of 2, 4 or 6 Gy and the ability to form colony was measured after 14 days. NPC cells with silenced expression of EIF4EBP1 displayed a significant decrease in the number of colonies after radiation treatment compared to negative control siRNA (<xref rid="f4-or-37-02-0913" ref-type="fig">Fig. 4B and C</xref>). Results from AO staining showed that silence of EIF4EBP1 enhanced radiation-induced autophagy as evidenced by an increase in red signal under radiation treatment (<xref rid="f4-or-37-02-0913" ref-type="fig">Fig. 4D</xref>).</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>We found that expression of miR-138-5p is one of the determining factors involved in modulating the sensitivity of NPC cells to radiation treatment. miR-138-5p controls the cell cycle related genes in hepatocellular carcinoma (<xref rid="b19-or-37-02-0913" ref-type="bibr">19</xref>). In NPC, the oncogenic cell cycle regulator CCND1 is a reported target of miR-138-5p (<xref rid="b9-or-37-02-0913" ref-type="bibr">9</xref>). In small cell lung cancer, inhibition of cell cycle progression is also observed in miR-138-5p overexpressing cells (<xref rid="b20-or-37-02-0913" ref-type="bibr">20</xref>). It is suggested that miR-138-5p might be involved in DNA damage response by targeting the histone H2AX (<xref rid="b20-or-37-02-0913" ref-type="bibr">20</xref>). Recently, the role of miR-138-5p in modulating the sensitivity to cancer therapeutics is reported. In prostate cancer, miR-138-5p regulates Kindlin-2, a regulator of integrin adhesion receptor which is frequently overexpressed in castration-resistant prostate cancer (<xref rid="b21-or-37-02-0913" ref-type="bibr">21</xref>). Suppressing Kindlin-2 could improve the sensitivity of prostate cancer cells to docetaxel (<xref rid="b21-or-37-02-0913" ref-type="bibr">21</xref>). Upregulating miR-138-5p could increase the responsiveness of lung cancer cells to radiation treatment (<xref rid="b22-or-37-02-0913" ref-type="bibr">22</xref>).</p>
<p>eIF4E is an oncogenic driver which could promote malignant transformation (<xref rid="b23-or-37-02-0913" ref-type="bibr">23</xref>,<xref rid="b24-or-37-02-0913" ref-type="bibr">24</xref>). Increased eIF4F expression is rarely found in the benign lesions (<xref rid="b25-or-37-02-0913" ref-type="bibr">25</xref>). High expression has been observed in cancer with aggressive cancer and poorly differentiated phenotype (<xref rid="b26-or-37-02-0913" ref-type="bibr">26</xref>). Overexpression of eIF4F is also found in cancers of the head and neck regions including oral cavity, oropharynx, larynx and nasopharynx (<xref rid="b27-or-37-02-0913" ref-type="bibr">27</xref>&#x2013;<xref rid="b29-or-37-02-0913" ref-type="bibr">29</xref>). In NPC, high eIF4F expression promotes proliferation and cell cycle progression with high correlation to the oncogenic protein c-Myc and MMP9 (<xref rid="b29-or-37-02-0913" ref-type="bibr">29</xref>). As the cancer cell responses to radiation damage by activating the cell cycle checkpoints, it is suggested that eIF4E might function in radiation response by initiating expression of genes involved in cell cycle regulation (<xref rid="b30-or-37-02-0913" ref-type="bibr">30</xref>,<xref rid="b31-or-37-02-0913" ref-type="bibr">31</xref>). Apart from the protein translation function, eIF4E can promote oncogenic transformation by preferential export of capped mRNAs containing 50-nucleotide structural element in the 3&#x2032; UTR (<xref rid="b32-or-37-02-0913" ref-type="bibr">32</xref>).</p>
<p>Inactivation of the eIF4E inhibitor EIF4EBP1 could be achieved by phosphorylation. The serine/threonine protein kinase mammalian target of rapamycin (mTOR) is a critical player involved in EIF4EBP1 phosphorylation and dissociating from eIF4E (<xref rid="b33-or-37-02-0913" ref-type="bibr">33</xref>). Another serine/threonine protein kinase Akt, upstream of mTOR, is an indicator of poor prognosis of NPC patients. Activated Akt showed high correlation with the inactivated EIF4EBP1, which is a strong indication of the involvement of Akt signaling in EIF4EBP1 regulation (<xref rid="b34-or-37-02-0913" ref-type="bibr">34</xref>). Akt/mTOR signaling can be activated by radiation. Thus, the use of Akt/mTOR inhibitors could increase the sensitivity of cancer cells to radiation (<xref rid="b35-or-37-02-0913" ref-type="bibr">35</xref>).</p>
<p>In general, hypoxic cells are less sensitive to radiation treatment due to the specific expression of particular proteins in the hypoxic environment (<xref rid="b36-or-37-02-0913" ref-type="bibr">36</xref>). It has been shown that EIF4EBP1 expression will affect the cancer proteomic leading to the differential expression of different proteins under normoxic and hypoxic conditions (<xref rid="b37-or-37-02-0913" ref-type="bibr">37</xref>). The quantity of EIF4EBP1 protein and activated EIF4EBP1 was induced in response to radiation treatment (<xref rid="b38-or-37-02-0913" ref-type="bibr">38</xref>). In glioblastoma, inhibiting EIF4EBP1 could sensitize the xenograft to radiation (<xref rid="b39-or-37-02-0913" ref-type="bibr">39</xref>). Thus, it is important to explore the functional impact and the role of EIF4EBP1 in the radiation responses.</p>
<p>In conclusion, our results indicate that miR-138-5p mediates the responsiveness of NPC to ionizing radiation by targeting EIF4EBP1. Further study on the impact of miR-138-5p and EIF4EBP1 on the radiosensitivity of tumor cells will be useful for the development of therapeutic regimens to enhance the therapeutic radiosensitivity of NPC.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>This study was supported by S.K. Yee Medical Foundation Grant and Seed Funding of Basic Research, The University of Hong Kong.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="b1-or-37-02-0913"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>WI</given-names></name><name><surname>Sham</surname><given-names>JS</given-names></name></person-group><article-title>Nasopharyngeal carcinoma</article-title><source>Lancet</source><volume>365</volume><fpage>2041</fpage><lpage>2054</lpage><year>2005</year><pub-id pub-id-type="doi">10.1016/S0140-6736(05)66698-6</pub-id><pub-id pub-id-type="pmid">15950718</pub-id></element-citation></ref>
<ref id="b2-or-37-02-0913"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>XP</given-names></name><name><surname>Yi</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>MY</given-names></name><name><surname>Li</surname><given-names>XH</given-names></name><name><surname>Yi</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>PF</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Peng</surname><given-names>F</given-names></name><name><surname>Tang</surname><given-names>CE</given-names></name><name><surname>Li</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Identification of biomarkers for predicting nasopharyngeal carcinoma response to radiotherapy by proteomics</article-title><source>Cancer Res</source><volume>70</volume><fpage>3450</fpage><lpage>3462</lpage><year>2010</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-4099</pub-id><pub-id pub-id-type="pmid">20406978</pub-id></element-citation></ref>
<ref id="b3-or-37-02-0913"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>SF</given-names></name><name><surname>Teo</surname><given-names>PM</given-names></name><name><surname>Shiu</surname><given-names>WW</given-names></name><name><surname>Tsao</surname><given-names>SY</given-names></name><name><surname>Leung</surname><given-names>TW</given-names></name></person-group><article-title>Clinical features and management of distant metastases of nasopharyngeal carcinoma</article-title><source>J Otolaryngol</source><volume>20</volume><fpage>27</fpage><lpage>29</lpage><year>1991</year><pub-id pub-id-type="pmid">1709423</pub-id></element-citation></ref>
<ref id="b4-or-37-02-0913"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>AW</given-names></name><name><surname>Poon</surname><given-names>YF</given-names></name><name><surname>Foo</surname><given-names>W</given-names></name><name><surname>Law</surname><given-names>SC</given-names></name><name><surname>Cheung</surname><given-names>FK</given-names></name><name><surname>Chan</surname><given-names>DK</given-names></name><name><surname>Tung</surname><given-names>SY</given-names></name><name><surname>Thaw</surname><given-names>M</given-names></name><name><surname>Ho</surname><given-names>JH</given-names></name></person-group><article-title>Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976&#x2013;1985: Overall survival and patterns of failure</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>23</volume><fpage>261</fpage><lpage>270</lpage><year>1992</year><pub-id pub-id-type="doi">10.1016/0360-3016(92)90740-9</pub-id><pub-id pub-id-type="pmid">1587745</pub-id></element-citation></ref>
<ref id="b5-or-37-02-0913"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JY</given-names></name><name><surname>Chow</surname><given-names>VL</given-names></name><name><surname>Tsang</surname><given-names>R</given-names></name><name><surname>Wei</surname><given-names>WI</given-names></name></person-group><article-title>Nasopharyngectomy for locally advanced recurrent nasopharyngeal carcinoma: Exploring the limits</article-title><source>Head Neck</source><volume>34</volume><fpage>923</fpage><lpage>928</lpage><year>2012</year><pub-id pub-id-type="doi">10.1002/hed.21855</pub-id><pub-id pub-id-type="pmid">21818821</pub-id></element-citation></ref>
<ref id="b6-or-37-02-0913"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>AW</given-names></name><name><surname>Ng</surname><given-names>WT</given-names></name><name><surname>Chan</surname><given-names>YH</given-names></name><name><surname>Sze</surname><given-names>H</given-names></name><name><surname>Chan</surname><given-names>C</given-names></name><name><surname>Lam</surname><given-names>TH</given-names></name></person-group><article-title>The battle against nasopharyngeal cancer</article-title><source>Radiother Oncol</source><volume>104</volume><fpage>272</fpage><lpage>278</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.radonc.2012.08.001</pub-id><pub-id pub-id-type="pmid">22938727</pub-id></element-citation></ref>
<ref id="b7-or-37-02-0913"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garzon</surname><given-names>R</given-names></name><name><surname>Calin</surname><given-names>GA</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name></person-group><article-title>MicroRNAs in cancer</article-title><source>Annu Rev Med</source><volume>60</volume><fpage>167</fpage><lpage>179</lpage><year>2009</year><pub-id pub-id-type="doi">10.1146/annurev.med.59.053006.104707</pub-id><pub-id pub-id-type="pmid">19630570</pub-id></element-citation></ref>
<ref id="b8-or-37-02-0913"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shenouda</surname><given-names>SK</given-names></name><name><surname>Alahari</surname><given-names>SK</given-names></name></person-group><article-title>MicroRNA function in cancer: Oncogene or a tumor suppressor?</article-title><source>Cancer Metastasis Rev</source><volume>28</volume><fpage>369</fpage><lpage>378</lpage><year>2009</year><pub-id pub-id-type="doi">10.1007/s10555-009-9188-5</pub-id><pub-id pub-id-type="pmid">20012925</pub-id></element-citation></ref>
<ref id="b9-or-37-02-0913"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Lv</surname><given-names>XB</given-names></name><name><surname>Wang</surname><given-names>XP</given-names></name><name><surname>Sang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><etal/></person-group><article-title>MiR-138 suppressed nasopharyngeal carcinoma growth and tumorigenesis by targeting the CCND1 oncogene</article-title><source>Cell Cycle</source><volume>11</volume><fpage>2495</fpage><lpage>2506</lpage><year>2012</year><pub-id pub-id-type="doi">10.4161/cc.20898</pub-id><pub-id pub-id-type="pmid">22739938</pub-id></element-citation></ref>
<ref id="b10-or-37-02-0913"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pause</surname><given-names>A</given-names></name><name><surname>Belsham</surname><given-names>GJ</given-names></name><name><surname>Gingras</surname><given-names>AC</given-names></name><name><surname>Donz&#x00E9;</surname><given-names>O</given-names></name><name><surname>Lin</surname><given-names>TA</given-names></name><name><surname>Lawrence</surname><given-names>JC</given-names><suffix>Jr</suffix></name><name><surname>Sonenberg</surname><given-names>N</given-names></name></person-group><article-title>Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5&#x2032;-cap function</article-title><source>Nature</source><volume>371</volume><fpage>762</fpage><lpage>767</lpage><year>1994</year><pub-id pub-id-type="doi">10.1038/371762a0</pub-id><pub-id pub-id-type="pmid">7935836</pub-id></element-citation></ref>
<ref id="b11-or-37-02-0913"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meric</surname><given-names>F</given-names></name><name><surname>Hunt</surname><given-names>KK</given-names></name></person-group><article-title>Translation initiation in cancer: A novel target for therapy</article-title><source>Mol Cancer Ther</source><volume>1</volume><fpage>971</fpage><lpage>979</lpage><year>2002</year><pub-id pub-id-type="pmid">12481419</pub-id></element-citation></ref>
<ref id="b12-or-37-02-0913"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Shang</surname><given-names>ZF</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>S</given-names></name></person-group><article-title>PC-1/PrLZ confers resistance to rapamycin in prostate cancer cells through increased 4E-BP1 stability</article-title><source>Oncotarget</source><volume>6</volume><fpage>20356</fpage><lpage>20369</lpage><year>2015</year><pub-id pub-id-type="doi">10.18632/oncotarget.3931</pub-id><pub-id pub-id-type="pmid">26011939</pub-id><pub-id pub-id-type="pmcid">4653010</pub-id></element-citation></ref>
<ref id="b13-or-37-02-0913"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glaser</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>HY</given-names></name><name><surname>Yao</surname><given-names>KT</given-names></name><name><surname>Zhu</surname><given-names>HC</given-names></name><name><surname>Wang</surname><given-names>FX</given-names></name><name><surname>Li</surname><given-names>GY</given-names></name><name><surname>Wen</surname><given-names>DS</given-names></name><name><surname>Li</surname><given-names>YP</given-names></name></person-group><article-title>Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas</article-title><source>Proc Natl Acad Sci USA</source><volume>86</volume><fpage>9524</fpage><lpage>9528</lpage><year>1989</year><pub-id pub-id-type="doi">10.1073/pnas.86.23.9524</pub-id><pub-id pub-id-type="pmid">2556716</pub-id><pub-id pub-id-type="pmcid">298529</pub-id></element-citation></ref>
<ref id="b14-or-37-02-0913"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>DP</given-names></name><name><surname>Ho</surname><given-names>JH</given-names></name><name><surname>Poon</surname><given-names>YF</given-names></name><name><surname>Chew</surname><given-names>EC</given-names></name><name><surname>Saw</surname><given-names>D</given-names></name><name><surname>Lui</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>CL</given-names></name><name><surname>Mak</surname><given-names>LS</given-names></name><name><surname>Lai</surname><given-names>SH</given-names></name><name><surname>Lau</surname><given-names>WH</given-names></name></person-group><article-title>Establishment of a cell line (NPC/HK1) from a differentiated squamous carcinoma of the nasopharynx</article-title><source>Int J Cancer</source><volume>26</volume><fpage>127</fpage><lpage>132</lpage><year>1980</year><pub-id pub-id-type="doi">10.1002/ijc.2910260202</pub-id><pub-id pub-id-type="pmid">6259064</pub-id></element-citation></ref>
<ref id="b15-or-37-02-0913"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>LJ</given-names></name><name><surname>Yang</surname><given-names>LX</given-names></name></person-group><article-title>Gamma-H2AX - a novel biomarker for DNA double-strand breaks</article-title><source>In Vivo</source><volume>22</volume><fpage>305</fpage><lpage>309</lpage><year>2008</year><pub-id pub-id-type="pmid">18610740</pub-id></element-citation></ref>
<ref id="b16-or-37-02-0913"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paglin</surname><given-names>S</given-names></name><name><surname>Hollister</surname><given-names>T</given-names></name><name><surname>Delohery</surname><given-names>T</given-names></name><name><surname>Hackett</surname><given-names>N</given-names></name><name><surname>McMahill</surname><given-names>M</given-names></name><name><surname>Sphicas</surname><given-names>E</given-names></name><name><surname>Domingo</surname><given-names>D</given-names></name><name><surname>Yahalom</surname><given-names>J</given-names></name></person-group><article-title>A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles</article-title><source>Cancer Res</source><volume>61</volume><fpage>439</fpage><lpage>444</lpage><year>2001</year><pub-id pub-id-type="pmid">11212227</pub-id></element-citation></ref>
<ref id="b17-or-37-02-0913"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tilton</surname><given-names>SC</given-names></name><name><surname>Tal</surname><given-names>TL</given-names></name><name><surname>Scroggins</surname><given-names>SM</given-names></name><name><surname>Franzosa</surname><given-names>JA</given-names></name><name><surname>Peterson</surname><given-names>ES</given-names></name><name><surname>Tanguay</surname><given-names>RL</given-names></name><name><surname>Waters</surname><given-names>KM</given-names></name></person-group><article-title>Bioinformatics Resource Manager v2.3: An integrated software environment for systems biology with microRNA and cross-species analysis tools</article-title><source>BMC Bioinformatics</source><volume>13</volume><fpage>311</fpage><year>2012</year><pub-id pub-id-type="doi">10.1186/1471-2105-13-311</pub-id><pub-id pub-id-type="pmid">23174015</pub-id><pub-id pub-id-type="pmcid">3534564</pub-id></element-citation></ref>
<ref id="b18-or-37-02-0913"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhodes</surname><given-names>DR</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Shanker</surname><given-names>K</given-names></name><name><surname>Deshpande</surname><given-names>N</given-names></name><name><surname>Varambally</surname><given-names>R</given-names></name><name><surname>Ghosh</surname><given-names>D</given-names></name><name><surname>Barrette</surname><given-names>T</given-names></name><name><surname>Pandey</surname><given-names>A</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name></person-group><article-title>ONCOMINE: A cancer microarray database and integrated data-mining platform</article-title><source>Neoplasia</source><volume>6</volume><fpage>1</fpage><lpage>6</lpage><year>2004</year><pub-id pub-id-type="doi">10.1016/S1476-5586(04)80047-2</pub-id><pub-id pub-id-type="pmid">15068665</pub-id><pub-id pub-id-type="pmcid">1635162</pub-id></element-citation></ref>
<ref id="b19-or-37-02-0913"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>LJ</given-names></name><name><surname>Tan</surname><given-names>YX</given-names></name><name><surname>Ren</surname><given-names>H</given-names></name><name><surname>Qi</surname><given-names>ZT</given-names></name></person-group><article-title>MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma</article-title><source>Carcinogenesis</source><volume>33</volume><fpage>1113</fpage><lpage>1120</lpage><year>2012</year><pub-id pub-id-type="doi">10.1093/carcin/bgs113</pub-id><pub-id pub-id-type="pmid">22362728</pub-id><pub-id pub-id-type="pmcid">3334515</pub-id></element-citation></ref>
<ref id="b20-or-37-02-0913"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>R</given-names></name><name><surname>Luo</surname><given-names>H</given-names></name></person-group><article-title>MicroRNA-138 regulates DNA damage response in small cell lung cancer cells by directly targeting H2AX</article-title><source>Cancer Invest</source><volume>33</volume><fpage>126</fpage><lpage>136</lpage><year>2015</year><pub-id pub-id-type="doi">10.3109/07357907.2015.1006329</pub-id><pub-id pub-id-type="pmid">25699650</pub-id></element-citation></ref>
<ref id="b21-or-37-02-0913"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sossey-Alaoui</surname><given-names>K</given-names></name><name><surname>Plow</surname><given-names>EF</given-names></name></person-group><article-title>miR-138-mediated regulation of KINDLIN-2 expression modulates sensitivity to chemotherapeutics</article-title><source>Mol Cancer Res</source><volume>14</volume><fpage>228</fpage><lpage>238</lpage><year>2016</year><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-15-0299</pub-id><pub-id pub-id-type="pmid">26474967</pub-id><pub-id pub-id-type="pmcid">4755782</pub-id></element-citation></ref>
<ref id="b22-or-37-02-0913"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Zang</surname><given-names>W</given-names></name><name><surname>Yin</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Chu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Up-regulation of microRNA-138 induce radiosensitization in lung cancer cells</article-title><source>Tumour Biol</source><volume>35</volume><fpage>6557</fpage><lpage>6565</lpage><year>2014</year><pub-id pub-id-type="doi">10.1007/s13277-014-1879-z</pub-id><pub-id pub-id-type="pmid">24691972</pub-id></element-citation></ref>
<ref id="b23-or-37-02-0913"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsson</surname><given-names>O</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Issaenko</surname><given-names>OA</given-names></name><name><surname>Avdulov</surname><given-names>S</given-names></name><name><surname>Peterson</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>K</given-names></name><name><surname>Bitterman</surname><given-names>PB</given-names></name><name><surname>Polunovsky</surname><given-names>VA</given-names></name></person-group><article-title>Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors</article-title><source>Cancer Res</source><volume>67</volume><fpage>6814</fpage><lpage>6824</lpage><year>2007</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-0752</pub-id><pub-id pub-id-type="pmid">17638893</pub-id></element-citation></ref>
<ref id="b24-or-37-02-0913"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avdulov</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Michalek</surname><given-names>V</given-names></name><name><surname>Burrichter</surname><given-names>D</given-names></name><name><surname>Peterson</surname><given-names>M</given-names></name><name><surname>Perlman</surname><given-names>DM</given-names></name><name><surname>Manivel</surname><given-names>JC</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name><name><surname>Yee</surname><given-names>D</given-names></name><name><surname>Bitterman</surname><given-names>PB</given-names></name><etal/></person-group><article-title>Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells</article-title><source>Cancer Cell</source><volume>5</volume><fpage>553</fpage><lpage>563</lpage><year>2004</year><pub-id pub-id-type="doi">10.1016/j.ccr.2004.05.024</pub-id><pub-id pub-id-type="pmid">15193258</pub-id></element-citation></ref>
<ref id="b25-or-37-02-0913"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Xie</surname><given-names>G</given-names></name><name><surname>Wen</surname><given-names>Q</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Fan</surname><given-names>S</given-names></name></person-group><article-title>Phosphorylated Mnk1 and eIF4E are associated with lymph node metastasis and poor prognosis of nasopharyngeal carcinoma</article-title><source>PLoS One</source><volume>9</volume><fpage>e89220</fpage><year>2014</year><pub-id pub-id-type="doi">10.1371/journal.pone.0089220</pub-id><pub-id pub-id-type="pmid">24551240</pub-id><pub-id pub-id-type="pmcid">3925237</pub-id></element-citation></ref>
<ref id="b26-or-37-02-0913"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Benedetti</surname><given-names>A</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name></person-group><article-title>eIF4E expression in tumors: Its possible role in progression of malignancies</article-title><source>Int J Biochem Cell Biol</source><volume>31</volume><fpage>59</fpage><lpage>72</lpage><year>1999</year><pub-id pub-id-type="doi">10.1016/S1357-2725(98)00132-0</pub-id><pub-id pub-id-type="pmid">10216944</pub-id></element-citation></ref>
<ref id="b27-or-37-02-0913"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nathan</surname><given-names>CO</given-names></name><name><surname>Franklin</surname><given-names>S</given-names></name><name><surname>Abreo</surname><given-names>FW</given-names></name><name><surname>Nassar</surname><given-names>R</given-names></name><name><surname>de Benedetti</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name><name><surname>Stucker</surname><given-names>FJ</given-names></name></person-group><article-title>Expression of eIF4E during head and neck tumorigenesis: Possible role in angiogenesis</article-title><source>Laryngoscope</source><volume>109</volume><fpage>1253</fpage><lpage>1258</lpage><year>1999</year><pub-id pub-id-type="doi">10.1097/00005537-199908000-00013</pub-id><pub-id pub-id-type="pmid">10443829</pub-id></element-citation></ref>
<ref id="b28-or-37-02-0913"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorrells</surname><given-names>DL</given-names><suffix>Jr</suffix></name><name><surname>Ghali</surname><given-names>GE</given-names></name><name><surname>De Benedetti</surname><given-names>A</given-names></name><name><surname>Nathan</surname><given-names>CO</given-names></name><name><surname>Li</surname><given-names>BD</given-names></name></person-group><article-title>Progressive amplification and overexpression of the eukaryotic initiation factor 4E gene in different zones of head and neck cancers</article-title><source>J Oral Maxillofac Surg</source><volume>57</volume><fpage>294</fpage><lpage>299</lpage><year>1999</year><pub-id pub-id-type="doi">10.1016/S0278-2391(99)90676-6</pub-id><pub-id pub-id-type="pmid">10077200</pub-id></element-citation></ref>
<ref id="b29-or-37-02-0913"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Di</surname><given-names>X</given-names></name><name><surname>Kang</surname><given-names>H</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>K</given-names></name><name><surname>Pang</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>EIF4E over-expresses and enhances cell proliferation and cell cycle progression in nasopharyngeal carcinoma</article-title><source>Med Oncol</source><volume>30</volume><fpage>400</fpage><year>2013</year><pub-id pub-id-type="doi">10.1007/s12032-012-0400-z</pub-id><pub-id pub-id-type="pmid">23277284</pub-id></element-citation></ref>
<ref id="b30-or-37-02-0913"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawlik</surname><given-names>TM</given-names></name><name><surname>Keyomarsi</surname><given-names>K</given-names></name></person-group><article-title>Role of cell cycle in mediating sensitivity to radiotherapy</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>59</volume><fpage>928</fpage><lpage>942</lpage><year>2004</year><pub-id pub-id-type="doi">10.1016/j.ijrobp.2004.03.005</pub-id><pub-id pub-id-type="pmid">15234026</pub-id></element-citation></ref>
<ref id="b31-or-37-02-0913"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Culjkovic</surname><given-names>B</given-names></name><name><surname>Topisirovic</surname><given-names>I</given-names></name><name><surname>Skrabanek</surname><given-names>L</given-names></name><name><surname>Ruiz-Gutierrez</surname><given-names>M</given-names></name><name><surname>Borden</surname><given-names>KL</given-names></name></person-group><article-title>eIF4E is a central node of an RNA regulon that governs cellular proliferation</article-title><source>J Cell Biol</source><volume>175</volume><fpage>415</fpage><lpage>426</lpage><year>2006</year><pub-id pub-id-type="doi">10.1083/jcb.200607020</pub-id><pub-id pub-id-type="pmid">17074885</pub-id><pub-id pub-id-type="pmcid">2064519</pub-id></element-citation></ref>
<ref id="b32-or-37-02-0913"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Culjkovic-Kraljacic</surname><given-names>B</given-names></name><name><surname>Baguet</surname><given-names>A</given-names></name><name><surname>Volpon</surname><given-names>L</given-names></name><name><surname>Amri</surname><given-names>A</given-names></name><name><surname>Borden</surname><given-names>KL</given-names></name></person-group><article-title>The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation</article-title><source>Cell Rep</source><volume>2</volume><fpage>207</fpage><lpage>215</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.celrep.2012.07.007</pub-id><pub-id pub-id-type="pmid">22902403</pub-id><pub-id pub-id-type="pmcid">3463940</pub-id></element-citation></ref>
<ref id="b33-or-37-02-0913"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goberdhan</surname><given-names>DCI</given-names></name><name><surname>Boyd</surname><given-names>CAR</given-names></name></person-group><article-title>mTOR: Dissecting regulation and mechanism of action to understand human disease</article-title><source>Biochem Soc Trans</source><volume>37</volume><fpage>213</fpage><lpage>216</lpage><year>2009</year><pub-id pub-id-type="doi">10.1042/BST0370213</pub-id><pub-id pub-id-type="pmid">19143634</pub-id><pub-id pub-id-type="pmcid">2639772</pub-id></element-citation></ref>
<ref id="b34-or-37-02-0913"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Wen</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Xie</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Chu</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Activation of Akt/mTOR pathway is associated with poor prognosis of nasopharyngeal carcinoma</article-title><source>PLoS One</source><volume>9</volume><fpage>e106098</fpage><year>2014</year><pub-id pub-id-type="doi">10.1371/journal.pone.0106098</pub-id><pub-id pub-id-type="pmid">25165983</pub-id><pub-id pub-id-type="pmcid">4148345</pub-id></element-citation></ref>
<ref id="b35-or-37-02-0913"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albert</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>KW</given-names></name><name><surname>Cao</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name></person-group><article-title>Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer</article-title><source>Mol Cancer Ther</source><volume>5</volume><fpage>1183</fpage><lpage>1189</lpage><year>2006</year><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-05-0400</pub-id><pub-id pub-id-type="pmid">16731750</pub-id></element-citation></ref>
<ref id="b36-or-37-02-0913"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>JM</given-names></name></person-group><article-title>The hypoxic cell: A target for selective cancer therapy - eighteenth Bruce F. Cain Memorial Award lecture</article-title><source>Cancer Res</source><volume>59</volume><fpage>5863</fpage><lpage>5870</lpage><year>1999</year><pub-id pub-id-type="pmid">10606224</pub-id></element-citation></ref>
<ref id="b37-or-37-02-0913"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magagnin</surname><given-names>MG</given-names></name><name><surname>van den Beucken</surname><given-names>T</given-names></name><name><surname>Sergeant</surname><given-names>K</given-names></name><name><surname>Lambin</surname><given-names>P</given-names></name><name><surname>Koritzinsky</surname><given-names>M</given-names></name><name><surname>Devreese</surname><given-names>B</given-names></name><name><surname>Wouters</surname><given-names>BG</given-names></name></person-group><article-title>The mTOR target 4E-BP1 contributes to differential protein expression during normoxia and hypoxia through changes in mRNA translation efficiency</article-title><source>Proteomics</source><volume>8</volume><fpage>1019</fpage><lpage>1028</lpage><year>2008</year><pub-id pub-id-type="doi">10.1002/pmic.200700551</pub-id><pub-id pub-id-type="pmid">18219697</pub-id></element-citation></ref>
<ref id="b38-or-37-02-0913"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braunstein</surname><given-names>S</given-names></name><name><surname>Badura</surname><given-names>ML</given-names></name><name><surname>Xi</surname><given-names>Q</given-names></name><name><surname>Formenti</surname><given-names>SC</given-names></name><name><surname>Schneider</surname><given-names>RJ</given-names></name></person-group><article-title>Regulation of protein synthesis by ionizing radiation</article-title><source>Mol Cell Biol</source><volume>29</volume><fpage>5645</fpage><lpage>5656</lpage><year>2009</year><pub-id pub-id-type="doi">10.1128/MCB.00711-09</pub-id><pub-id pub-id-type="pmid">19704005</pub-id><pub-id pub-id-type="pmcid">2772731</pub-id></element-citation></ref>
<ref id="b39-or-37-02-0913"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubois</surname><given-names>L</given-names></name><name><surname>Magagnin</surname><given-names>MG</given-names></name><name><surname>Cleven</surname><given-names>AH</given-names></name><name><surname>Weppler</surname><given-names>SA</given-names></name><name><surname>Grenacher</surname><given-names>B</given-names></name><name><surname>Landuyt</surname><given-names>W</given-names></name><name><surname>Lieuwes</surname><given-names>N</given-names></name><name><surname>Lambin</surname><given-names>P</given-names></name><name><surname>Gorr</surname><given-names>TA</given-names></name><name><surname>Koritzinsky</surname><given-names>M</given-names></name><etal/></person-group><article-title>Inhibition of 4E-BP1 sensitizes U87 glioblastoma xenograft tumors to irradiation by decreasing hypoxia tolerance</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>73</volume><fpage>1219</fpage><lpage>1227</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.ijrobp.2008.12.003</pub-id><pub-id pub-id-type="pmid">19251093</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-or-37-02-0913" position="float">
<label>Figure 1.</label>
<caption><p>Overexpression of miR-138-5p enhanced the sensitivity of NPC cells to radiation. (A) QPCR analysis of miR-138-5p expression level in NPC cells transfected with miR-138 precursor. (B) Colony formation assay of NPC cells transfected with miR-138 precursor upon different doses of radiation treatment. (C) Representative images showing colony formation. Error bar indicate SD, n=3, &#x002A;p&#x003C;0.05, &#x002A;&#x002A;p&#x003C;0.01.</p></caption>
<graphic xlink:href="OR-37-02-0913-g00.tif"/>
</fig>
<fig id="f2-or-37-02-0913" position="float">
<label>Figure 2.</label>
<caption><p>Overexpression of miR-138-5p inhibited proliferation and enhanced the &#x03B3;H2AX foci formation and autophagy of NPC cells under radiation treatment. (A) Real-time monitoring of proliferation rate of NPC cells transfected with miR-138 precursor exposed to radiation treatment using xCELLigence Real-Time Cell Analyzer. Error bar indicates SD, n=3. (B) Cell index at different time-points. Error bar indicates SD, n=3. (C) The number of &#x03B3;H2AX foci of NPC transfected with miR-138 precursor upon radiation treatment. Error bar indicates SE, n=20. (D) Representative images showing &#x03B3;H2AX foci formation. (E) Representative images showing formation of acidic vesicular organelles in NPC cells transfected with miR-138 precursor exposed to radiation treatment. &#x002A;p&#x003C;0.05, &#x002A;&#x002A;p&#x003C;0.01.</p></caption>
<graphic xlink:href="OR-37-02-0913-g01.tif"/>
</fig>
<fig id="f3-or-37-02-0913" position="float">
<label>Figure 3.</label>
<caption><p>miR138-5p directly targets EIF4EBP1. (A) Integration of predicted targets of miR-138-5p and transcripts downregulated by miR-138-5p from microarray analysis identified EIF4EBP1 as a putative direct target of miR-138-5p. (B) The predicted miR-138-5p binding sequence located in the 3&#x2032;-UTR of EIF4EBP1 and the mutation of the miR-138-5p binding sequence for luciferase reporter assay. (C) QPCR detection of EIF4EBP1 expression in NPC cells transfected with miR-138 precursor. (D) Luciferase reporter assay of HONE1 cells co-transfected with Luc-wild-type vector or Luc-mutant vector and miR-138 precursor or negative control. Error bar indicates SD, n=3, &#x002A;&#x002A;p&#x003C;0.01. (E) Expression level of EIF4EBP1 in NPC and normal tissues in GSE12452 from Oncomine.</p></caption>
<graphic xlink:href="OR-37-02-0913-g02.tif"/>
</fig>
<fig id="f4-or-37-02-0913" position="float">
<label>Figure 4.</label>
<caption><p>Silence of EIF4EBP1 increased the sensitivity of NPC cells to radiation. (A) QPCR analysis of EIF4EBP1 expression level in NPC cells transfected with EIF4EBP1 siRNA. (B) Colony formation assay of NPC cells transfected with EIF4EBP1 siRNA upon different doses of radiation treatment. (C) Representative images showing colony formation. (D) Representative images showing formation of acidic vesicular organelles in NPC cells transfected with EIF4EBP1 siRNA upon radiation treatment. Error bar indicates SD, n=3, &#x002A;p&#x003C;0.05, &#x002A;&#x002A;p&#x003C;0.01.</p></caption>
<graphic xlink:href="OR-37-02-0913-g03.tif"/>
</fig>
</floats-group>
</article>